Company Encyclopedia
View More
name
Avenue Therap
ATXI.US
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
4.715 T
ATXI.USMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking107/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-121.42%E
    • Profit Margin-266.67%E
    • Gross Margin0.00%E
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY60.46%B
    • Total Assets YoY41.90%A
    • Net Assets YoY39.41%A
  • Cash ScoreD
    • Cash Flow Margin-37.50%D
    • OCF YoY0.00%D
  • Operating ScoreC
    • Turnover0.44C
  • Debt ScoreB
    • Gearing Ratio38.17%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Avenue Therapeutics Inc. Announces Date for Upcoming Annual Stockholder Meeting

    Avenue Therapeutics Inc. will hold its Annual Meeting of Stockholders virtually on December 30, 2025. Stockholders will vote on the election of six directors for a one-year term and ratify KPMG LLP as the independent registered public accounting firm for 2025. The meeting may also address other business matters.

    Reuters·
    US
    ATXI
    +1.37%
    Reuters·
    US
    ATXI
    +1.37%

    Avenue Therapeutics Reports Improved Financials Amid Challenges

    Avenue Therapeutics reported a Q3 net loss of $683,000, significantly improved from last year's $3.1 million loss, due to reduced operating expenses. The company earned $1.4 million from a terminated license agreement. Despite financial improvements, challenges persist, including Nasdaq delisting and financial uncertainties. Avenue is focused on securing funding for operations and a potential Phase 3 study for IV tramadol.

    Tip Ranks·
    US
    ATXI
    +1.37%
    Tip Ranks·
    US
    ATXI
    +1.37%

    Axsome Therapeutics Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics

    Axsome Therapeutics is acquiring Baergic Bio, a subsidiary of Avenue Therapeutics, along with global rights to BAER-101. The agreement includes a $0.3 million upfront payment and potential milestone payments totaling up to $79 million, plus royalties on global sales of AXS-17. Avenue Therapeutics will receive approximately 74% of future payments. Axsome aims to develop AXS-17 for epilepsy treatment, based on preclinical findings.

    Reuters·
    US
    AXSM
    -0.90%
    US
    ATXI
    +1.37%
    Reuters·
    US
    AXSM
    -0.90%
    US
    ATXI
    +1.37%

    Avenue Therap | 10-Q: FY2025 Q2 Revenue: USD 1.404 M

    LB filings·
    US
    ATXI
    +1.37%
    LB filings·
    US
    ATXI
    +1.37%

    Avenue Therap | 10-Q: FY2025 Q1 EPS: USD -0.62

    LB filings·
    US
    ATXI
    +1.37%
    LB filings·
    US
    ATXI
    +1.37%
    © 2025 Longbridge｜Disclaimer